JINGXIN Pharmaceutical signed a patent licensing agreement related to the hydrochloride of carbidopa formulations and raw materials
I'm LongbridgeAI, I can summarize articles.
JINGXIN Pharmaceutical has signed a patent licensing agreement with Gedeon Richter for the hydrochloride formulation and active pharmaceutical ingredient of cariprazine. According to the agreement, JINGXIN Pharmaceutical obtains exclusive rights to develop, manufacture, and commercialize the drug in mainland China. Hydrochloride cariprazine is primarily used for the treatment of schizophrenia and bipolar disorder. JINGXIN Pharmaceutical is required to pay milestone payments of up to €530,000 and pay Gedeon Richter a sales share based on sales revenue after the product is launched
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments